Financials
Financial year 2025
MEDIXA PHARMA from Lierneux, company number BE0849178283, closed financial year 2025 with a result of € 54,457 after tax. For that financial year MEDIXA PHARMA recorded a gross margin of € 137,313 and equity of € 492,598. Compared with financial year 2024, the result moved from € 57,377 to € 54,457. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2026.
€ 492,598
▲ 12% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 54,457
▼ 5% vs 2024
Profit after tax over the fiscal year.
€ 85,187
▲ 63% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 473,998.
People and assets in 2025
€ 4,746
▲ 26% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 143,421
▼ 19% vs 2024
€ 35,387 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 2,603
▲ 121% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 24,252
▲ 20% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 119,044 | € 144,942 | € 140,250 | € 137,313 | ▼ 2% |
| Profit after taxes | € 42,960 | € 60,468 | € 57,377 | € 54,457 | ▼ 5% |
| Equity | € 320,296 | € 380,764 | € 438,141 | € 492,598 | ▲ 12% |
| Total debts | € 1,107,810 | € 1,071,245 | € 1,017,669 | € 963,992 | ▼ 5% |
| Cash | € 19,592 | € 36,201 | € 52,395 | € 85,187 | ▲ 63% |
| Land & buildings | € 531,379 | € 540,799 | € 525,908 | € 497,456 | ▼ 5% |
| Retained profit | € 301,696 | € 362,164 | € 419,541 | € 473,998 | ▲ 13% |
| Bank debt | € 249,499 | € 219,205 | € 177,872 | € 143,421 | ▼ 19% |
| Balance sheet total | € 1,428,106 | € 1,452,009 | € 1,455,810 | € 1,456,590 |
Key figures of MEDIXA PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to MEDIXA PHARMA?
What happened at MEDIXA PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 54,457 (▼ 5% vs 2024). Source: NBB ↗
- New establishment in Lierneux. KBO
- Start of the company according to the CBE. KBO
In short
From € 42,960 profit in 2022 to € 54,457 profit in 2025.
Paid € 105,320 in corporate taxes since 2022.
Best year ever: 2023, with € 60,468 profit.
Management
Behind MEDIXA PHARMA is XAVIER LEJEUNE. It owns PHARMACIE LEJEUNE-VDM S.A. itself.
Directors
According to the 2025 annual accounts
XAVIER LEJEUNE
Managing director
Establishments
Establishment units
Physical locations of this company
Rue du Doyard 12
4990 Lierneux
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0849.178.283
- VAT number
- BE 0849.178.283
- Registered office
- Rue du Doyard 12, 4990 Lierneux
- Names & denominations
- MEDIXA PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 1 October 2012
- Peppol
- Active · Active since 13 Oct 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering